Can Novartis really make its medicines available to everyone?
Novartis launched a new strategy in sub-Saharan Africa in 2019. Sales people will no longer be incentivised by sales targets but rather by patients reached. Reuters / Baz Ratner
Swiss pharma firm Novartis has said it wants everyone in the world to be able to access its products, even multi-million-dollar gene therapies. Can its experiment work?
This content was published on February 10, 2021 - 09:00
February 10, 2021 - 09:00
Jessica Davis Plüss
Jessica covers the good, the bad, and the ugly when it comes to big global companies and their impact in Switzerland and abroad. She’s always looking for a Swiss connection with her native San Francisco and will happily discuss why her hometown has produced some of the greatest innovations but can’t seem to solve its housing crisis.
Infectious disease research ‘alarmingly low’
Inside a pharmacy in India. The COVID-19 pandemic has raised questions about equal access to medicines. Copyright: Trinity Care Foundation, (CC BY-NC-ND 2.0). This image has been cropped.
Speed read
Focus on COVID-19 threatens to further divert attention
‘Half of key medicines’ are missing from equitable access plans
Share this article:
Republish
We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
You have to credit our authors.
You have to credit SciDev.Net where possible include our logo with a link back to the original article.
¿Sin ganancias no funcionan las farmacéuticas? | ACTUALIDAD | DW dw.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dw.com Daily Mail and Mail on Sunday newspapers.